

Poster 44

In vitro and *in silico* evaluation of 5-MeO-DMT, LSD, and mescaline's interaction with CYP450 enzymes

Andreia Machado Brito-da-Costa ^{1,2,3,*}, Mariana Carvalho ^{1,2}, Ricardo Jorge Dinis-Oliveira ^{1,2,4,5}, Áurea Madureira-Carvalho ^{1,6}, Sérgio F. Sousa ^{7,*} and Diana Dias da Silva ^{1,3,6,8,*}

¹ Associate Laboratory i4HB - Institute for Health and Bioeconomy, Portugal

² UCIBIO - Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal

³ UCIBIO - Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

⁴ FOREN-Forensic Science Experts, Dr. Mário Moutinho Avenue, n.º 33-A, Lisbon, Portugal

⁵ Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal

⁶ UCIBIO - Applied Molecular Biosciences Unit, Forensics and Biomedical Sciences Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal

⁷ LAQV/REQUIMTE, BioSIM - Biomedicine Department, Faculty of Medicine, University of Porto, Porto, Portugal

⁸ LAQV/REQUIMTE, ESS, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida, 400 4200-072, Porto

* Correspondence: andreia.costa@iucs.cespu.pt (AMBC); sergiosousa@med.up.pt (SFS); dds@ess.ipp.pt (DDS)

Abstract

Background: 5-Methoxy-*N,N*-dimethyltryptamine (5-MeO-DMT), lysergic acid diethylamide (LSD), and mescaline are classic hallucinogens known for their recreational use, which increased in the last decades. Despite some available data on the metabolism of these drugs [1-3], a scientific gap exists regarding their possible interactions with CYP450 enzymes. Nevertheless, this information is of crucial relevance to predict drug-drug interactions and understand toxicological phenomena, in particular interindividual variability. **Objective:** This study aimed to evaluate *in vitro* and *in silico* the interaction of 5-MeO-DMT, LSD, and mescaline with the enzymes CYP2A6/2B6/2D6/2E1/3A4. **Methods:** The *in vitro* assessment of CYP450 inhibition was performed using the Vivid[®]CYP450 screening kits. IC₅₀ was calculated using GraphPad Prism 9.3.0. For *in silico* assessment, molecular dynamics were performed using the PMEMD.cuda module in AMBER16. Calculations were made on the last 100 ns of the trajectory (stable zone) to assess the interaction mode/strength between enzyme and ligand, namely MMGBSA, per-residue decomposition energy, and hydrogen bonds. **Results:** Based on the IC₅₀ (µM), LSD (0.35) and 5-MeO-DMT (3.47) present the capacity to be inhibitors of CYP2D6. Based on the MMGBSA (kcal/mol), LSD showed the highest binding affinities for all enzymes, while mescaline showed the lowest. The strong interaction of LSD with CYP2A6 is mediated by a hydrogen bond established with the protein residue Asn297. For interaction with CYP2B6, the residues Thr302 and Lys479 were important in mediating the interaction with 5-MeO-DMT and LSD. Key residues mediating the interaction of 5-MeO-DMT and LSD with CYP2D6 included Phe120, Leu213, and Phe483. For interaction with CYP2E1, residues Phe207, Phe298, and Thr303 are important; and for CYP3A4, an important hydrogen bond between LSD and Ala370 was identified. **Conclusions:** Both LSD and 5-MeO-DMT are predicted to have strong potential to be CYP2D6 inhibitors. A strong interaction was also identified *in silico* between LSD and CYP2A6.

Keywords: drug-drug interaction; hallucinogens; metabolism; pharmacokinetics; toxicology

Acknowledgments

This research was funded by i) FCT funds in the scope of the PhD grant 2021.04999.BD, the projects UIDP/04378/2020 and UIDB/04378/2020 of the UCIBIO, and the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy—i4HB; ii) TOXRUN-IUCS-CESPU funds in the scope of the project PsiloPharma_PI2RL_IINFACTS_2021; and iii) EUROX Pharma funds.

References

1. Dinis-Oliveira, R.J.; Pereira, C.L.; Dias da Silva, D. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. *Curr Mol Pharmacol* (2019), 12, 184-194.
2. Libânio Osório Marta, R.F. Metabolism of lysergic acid diethylamide (LSD): an update. *Drug Metab Rev* (2019), 51, 378-387.
3. Ermakova, A.O.; Dunbar, F.; Rucker, J.; Johnson, M.W. A narrative synthesis of research with 5-MeO-DMT. *J Psychopharmacol* (2022), 36, 273-294.



In *Scientific Letters*, works are published under a CC-BY license (Creative Commons Attribution 4.0 International License at <https://creativecommons.org/licenses/by/4.0/>), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use at <https://creativecommons.org/licenses/by/4.0/legalcode>).